How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting

被引：1

作者：

Sehouli, Jalid ^{[1
,2
]}

Boer, Jolijn ^{[2
]}

Brand, Alison H. ^{[3
,4
]}

Oza, Amit M. ^{[5
]}

O'Donnell, Jennifer ^{[4
]}

Bennett, Katherine ^{[4
]}

Glaspool, Ros ^{[6
]}

Lee, Chee Khoon ^{[7
]}

Ethier, Josee-Lyne ^{[8
]}

Harter, Philipp ^{[9
,10
]}

Seebacher-Shariat, Veronika ^{[11
,12
]}

Chang, Ting-Chang ^{[13
,14
]}

Cohen, Paul A. ^{[15
]}

van Gorp, Toon ^{[16
]}

Chavez-Blanco, Adriana ^{[4
]}

Welch, Stephen ^{[17
]}

Hranovska, Hanna ^{[18
]}

O'Toole, Sharon ^{[19
]}

Lok, Christianne A. R. ^{[20
]}

Madariaga, Ainhoa ^{[21
,22
]}

Rauh-Hain, Jose Alejandro ^{[23
]}

Perez Fidalgo, Alejandro ^{[24
]}

Tan, David ^{[25
]}

Michels, Judith ^{[26
,27
]}

Pothuri, Bhavana ^{[28
]}

Fujiwara, Noriko ^{[29
,30
]}

Rosengarten, Ora ^{[31
]}

Nishio, Hiroshi ^{[32
,33
]}

Kim, Se Ik ^{[34
]}

Mukopadhyay, Asima ^{[35
]}

Piovano, Elisa ^{[36
]}

Cecere, Sabrina Chiara ^{[37
]}

Kohn, Elise C. ^{[38
]}

Mukherjee, Uma ^{[39
]}

Nasser, Sara ^{[40
,41
]}

Lindemann, Kristina ^{[42
,43
]}

Croke, Jennifer ^{[44
]}

Chen, Xiaojun ^{[45
]}

Geissler, Franziska ^{[46
,47
]}

Bookman, Michael A. ^{[4
,48
]}

机构：

[1] Charite Univ Med Berlin, Gynecol Ctr Oncol Surg, Berlin, Germany

[2] North Eastern German Soc Gynaecol Oncol NOGGO eV, Berlin, Germany

[3] Westmead Hosp, Westmead, NSW, Australia

[4] Gynecol Canc InterGrp, Kingston, ON, Canada

[5] Princess Margaret Hosp Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada

[6] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[7] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

[8] Sunnybrook Hlth Sci Ctr, Div Med Oncol, Odette Canc Ctr, Toronto, ON, Canada

[9] Kliniken Essen Mitte Evangel Huyssens Stiftung Kn, Gynecol & Gynecol Oncol, Essen, Germany

[10] AGO Study Grp, Wiesbaden, Germany

[11] AGO Austria, Innsbruck, Austria

[12] Med Univ Vienna, Vienna, Austria

[13] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan

[14] Chang Gung Univ, Taoyuan, Taiwan

[15] Australia New Zealand Gynaecol Oncol Grp ANZGO, Camperdown, NSW, Australia

[16] Katholieke Univ Leuven, Univ Hosp Leuven, Gynaecol Oncol, Leuven, Belgium

[17] Western Univ, Schulich Sch Med & Dent, Dept Oncol, London, ON, Canada

[18] Nat Acad Med Sci Ukraine, Kiev, Ukraine

[19] Canc Trials Ireland, Dublin, Ireland

[20] Netherlands Canc Inst, Dept Gynaecol Oncol, Amsterdam, Netherlands

[21] 12 Octubre Univ Hosp, Madrid, Spain

[22] European Org Res Treatment Canc, Brussels, Belgium

[23] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[24] Hosp Clin Univ, Med Oncol, Valencia, Spain

[25] Nat Univ Canc Inst, Singapore, Singapore

[26] Gustave Roussy, Villejuif, France

[27] Univ Paris Saclay, Villejuif, France

[28] NYU Langone Hlth Perlmutter Canc Ctr, New York, NY USA

[29] Univ Tokyo, IMSUT Hosp, Inst Med Sci, Dept Palliat Med & Adv Clin Oncol, Tokyo, Japan

[30] Gynecol Oncol Trial & Invest Consortium GOTIC, Moroyama, Saitama, Japan

[31] Shaare Zedek Med Ctr, Med Gyneco Oncol Unit, Jerusalem, Israel

[32] Keio Univ, Sch Med, Dept Obstet & Gynecol, Keio, Tokyo, Japan

[33] Japanese Gynecol Oncol Grp JGOG, Tokyo, Japan

[34] Seoul Natl Univ Hosp, Obstetr & Gynecol, Seoul, South Korea

[35] Kolkata Gynecol Oncol Trials & Translat Res Grp, Kolkata, India

[36] Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy

[37] Natl Canc Inst, Inst Hospitalizat & Care Sci Fdn Pascale, Dep Expt Urogynecol Oncol, Naples, Italy

[38] NCI, Canc Therapy Evaluat Program, Clin Invest Branch, Rockville, MD USA

[39] GynaeOncol Trials Grp UK GCG UK, London, England

[40] Charite Univ Med Berlin, Ctr Oncol Surg, Dept Gynecol, Berlin, Germany

[41] Pan Arabian Res Soc Gynecol Oncol, Berlin, Germany

[42] Oslo Univ Hosp, Dept Gynecol Oncol, Oslo, Norway

[43] Nord Soc Gynaecol Oncol NSGO, Copenhagen, Denmark

[44] Princess Margaret Hosp Canc Ctr, Toronto, ON, Canada

[45] Tongji Univ, Dongfang Hosp, Shanghai, Peoples R China

[46] Univ Hosp Basel, Hosp Women, Dept Gynecol & Gynecol Oncol, Basel, Switzerland

[47] Swiss GO Trial Grp, Basel, Switzerland

[48] Kaiser Permanente Northern Calif, Oakland, CA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / 11期

关键词：

Cervical Cancer; Ovarian Cancer; Uterine Cancer; Vulvar and Vaginal Cancer; BARRIERS; REPRESENTATION; PARTICIPATION; RACE;

D O I：

10.1136/ijgc-2024-005982

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion of patients into trials has been widely criticized for inadequate representation of the real-world population. Ideally, patients enrolled in clinical trials should represent a broader population to enhance external validity and facilitate translation of outcomes across all relevant groups. Specifically, there has been a systematic lack of data for underrepresented groups, with many studies failing to report or differentiate study participants based on sociodemographic domains, such as race and ethnicity. As such, the impact of treatment in these underrepresented groups is poorly understood, and clinical outcomes according to various sociodemographic factors are infrequently assessed. Inclusion of diverse trial participants, with different racial and ethnic background, is essential for the understanding of factors that may impact clinical outcomes. Therefore, we conducted a multi-national meeting of clinical trial groups and industry with the goal of increasing equity, diversity, and inclusion in gynecologic cancer clinical trials and to address barriers to recruitment, participation, and harmonization of data collection and reporting. These Gynecologic Cancer Intergroup (GCIG) statements present recommendations and strategies for the gynecologic cancer research community to improve equity, diversity, and inclusion in gynecologic cancer clinical trials.

引用

页码：1677 / 1684

页数：8

共 8 条

[1] Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting Taking Endometrial Cancer Trials Into the Translational Era
Creutzberg, Carien L.
Kitchener, Henry C.
Birrer, Michael J.
Landoni, Fabio
Lu, Karen H.
Powell, Melanie
Aghajanian, Carol
Edmondson, Richard
Goodfellow, Paul J.
Quinn, Michael
Salvesen, Helga B.
Thomas, Gillian
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08) : 1528 - 1534
[2] Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)
Pothuri, B.
Blank, S. V.
Myers, T. K.
Hines, J. F.
Randall, L. M.
O'Cearbhaill, R. E.
Slomovitz, B. M.
Eskander, R. N.
Secord, A. Alvarez
Coleman, R. L.
Walker, J. L.
Monk, B. J.
Moore, K. N.
O'Malley, D. M.
Copeland, L. J.
Herzog, T. J.
GYNECOLOGIC ONCOLOGY, 2023, 174 : 278 - 287
[3] Current Academic Clinical Trials in Ovarian Cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009
Trimble, Edward L.
Birrer, Michael J.
Hoskins, William J.
Marth, Christian
Petryshyn, Ray
Quinn, Michael
Thomas, Gillian M.
Kitchener, Henry C.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (07) : 1284 - 1298
[4] Trackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry
McKay, Rana R.
Gold, Theresa
Zarif, Jelani C.
Chowdhury-Paulino, Ilkania M.
Friedant, Adam
Gerke, Travis
Grant, Marie
Hawthorne, Kelly
Heath, Elisabeth
Huang, Franklin W.
Jackson, Maria D.
Mahal, Brandon
Ogbeide, Osarenren
Paich, Kellie
Ragin, Camille
Rencsok, Emily M.
Simmons, Stacey
Yates, Clayton
Vinson, Jake
Kantoff, Philip W.
George, Daniel J.
Mucci, Lorelei A.
JCO GLOBAL ONCOLOGY, 2021, 7 : 495 - 505
[5] Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel program
Gerber, David E.
Tiro, Jasmin A.
McNeill, Lorna H.
Williams, Erin L.
Zhu, Hong
Lee, Simon J. Craddock
Leavey, Patrick J.
Sadeghi, Navid
Kapinos, Kandice A.
Dornsife, Dana L.
Nguyen, Vivian
Wileyto, E. Paul
Guerra, Carmen E.
CONTEMPORARY CLINICAL TRIALS, 2022, 121
[6] How close are we from achieving demographic diversity in clinical trials? Insights from Singapore
Yi, Yueyang
Lam, Thomas Yuen Tung
ANNALS ACADEMY OF MEDICINE SINGAPORE, 2024, 53 (07) : 407 - 409
[7] Ethical conflict in providing informed consent for clinical trials: A problematic example from the gynecologic cancer research community
Markman, M
ONCOLOGIST, 2004, 9 (01) : 3 - 7
[8] Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
Bookman, M. A.
Okamoto, A.
Stuart, G.
Yanaihara, N.
Aoki, D.
Bacon, M.
Fujiwara, K.
Gonzalez-Martin, A.
Harter, P.
Kim, J. W.
Ledermann, J.
Pujade-Lauraine, E.
Quinn, M.
Ochiai, K.
ANNALS OF ONCOLOGY, 2017, 28 : 30 - 35

← 1 →